ClinicalTrials.gg
CompletedNCT03215706CheckMate 9LAUpdated Dec 17, 2025Results posted

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

A Phase 3 interventional study of Ipilimumab and Nivolumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 116 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
719
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 13 under way, none of them phase 3. Ipilimumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 47
719 · median 39
Started
2017
with 10 others
Phase 3
10 of 47
none open now
Registered
21st of 47
by date
Lead sponsor
13 of 47
Bristol-Myers Squibb

Among the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 11 that started in 2017, is one of 10 in phase 3, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Participants with confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
  • (ECOG) Performance Status of ≤ 1
  • by CT or MRI per version 1.1 (RECIST 1.1) criteria
  • Participants must have IHC testing with results performed by a central laboratory during the screening period

Exclusion criteria

Exclusion Criteria:

  • Participants with known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations) are excluded
  • Participants with known anaplastic lymphoma kinase (ALK) translocations which are sensitive to available targeted inhibitor therapy are excluded
  • Participants with untreated are excluded. Participants are eligible if CNS metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to first treatment

Other protocol inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
719 participants (actual)

Study arms

  • Experimental
    Module A

    Chemotherapy/Biologics combined

    Biological: Ipilimumab · Biological: Nivolumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin

  • Active comparator
    Module B

    Chemotherapy Combination

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • BiologicalIpilimumab

    Specified dose on specified day

    Also known as: Yervoy, BMS734016

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: Opdivo, BMS936558

  • Specified dose on specified day

  • Specified dose on specified day

    Also known as: Taxol

  • Specified dose on specified day

    Also known as: Alimta

  • Specified dose on specified day

    Also known as: Platinol

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

    Time frame: From date of randomization to date of death (assessed up to October 2019, approximately 23 months)

Secondary outcomes

  1. Progression Free Survival (PFS) by BICR

    PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  2. Objective Response Rate (ORR) by BICR

    ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  3. Duration of Response (DoR)

    DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  4. Time to Response (TTR)

    TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  5. Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression

    ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \<1%, not quantifiable, ≥50%, or 1-49%.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  6. PFS by BICR by PD-L1 Tumor Cell Expression

    PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  7. OS by PD-L1 Tumor Cell Expression

    OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

    Time frame: From date of randomization to date of death (assessed up to October 2024, approximately 72 months)

  8. PFS by BICR by Tumor Mutational Burden

    PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  9. ORR by BICR by Tumor Mutational Burden

    ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.

    Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

  10. OS by Tumor Mutational Burden

    OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

    Time frame: From date of randomization to date of death (assessed up to October 2024, approximately 72 months)

07

Results

Posted Sep 16, 2020

Participant flow

Randomization
Participant flow — Randomization
MilestoneTreatment ATreatment B
Started361358
Completed358349
Not completed39
Withdrew: Adverse event unrelated to study drug10
Withdrew: Participant withdrew consent13
Withdrew: No longer meets study criteria14
Withdrew: Other reasons02
Treatment Period
Participant flow — Treatment Period
MilestoneTreatment ATreatment B
Started358349
Completed49100
Not completed309249
Withdrew: Disease progression184174
Withdrew: Study drug toxicity7024
Withdrew: Death71
Withdrew: Adverse event unrelated to study drug3127
Withdrew: Request to d/c treatment210
Withdrew: Participant withdrew consent45
Withdrew: Lost to follow-up01
Withdrew: Administrative reason by sponsor02
Withdrew: Other reasons105
Withdrew: Not reported10

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

Time frame:
From date of randomization to date of death (assessed up to October 2019, approximately 23 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment ATreatment B
Overall Survival (OS)14.13 (13.24 to 16.16)10.74 (9.46 to 12.45)
Statistical analysis
  • Treatment A vs Treatment B · Log-rank test stratified · p = 0.0006 · Hazard ratio (hr): 0.69 · 95% CI 0.56 to 0.86
SecondaryProgression Free Survival (PFS) by BICR

PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
Progression Free Survival (PFS) by BICR
MonthsTreatment ATreatment B
Progression Free Survival (PFS) by BICR6.74 (5.55 to 8.05)5.26 (4.37 to 5.59)
Statistical analysis
  • Treatment A vs Treatment B · Log-rank test stratified · Hazard ratio (hr): 0.70 · 95% CI 0.59 to 0.82
SecondaryObjective Response Rate (ORR) by BICR

ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) by BICR
Percentage of ParticipantsTreatment ATreatment B
Objective Response Rate (ORR) by BICR38.0 (32.9 to 43.2)25.1 (20.7 to 30.0)
Statistical analysis
  • Treatment A vs Treatment B · Mantel Haenszel · Odds ratio (or): 12.7 · 95% CI 6.0 to 19.4
SecondaryDuration of Response (DoR)

DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsTreatment ATreatment B
Duration of Response (DoR)13.01 (8.71 to 20.21)5.59 (4.37 to 7.10)
SecondaryTime to Response (TTR)

TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsTreatment ATreatment B
Time to Response (TTR)2.53 (1.1 to 52.1)1.58 (1.2 to 22.2)
SecondaryObjective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression

ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \<1%, not quantifiable, ≥50%, or 1-49%.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression
Percentage of ParticipantsTreatment ATreatment B
BASELINE PD-L1 EXPRESSION ≥1%42.6 (35.8 to 49.7)27.5 (21.5 to 34.1)
BASELINE PD-L1 EXPRESSION < 1%31.1 (23.4 to 39.6)20.2 (13.6 to 28.1)
Non-Quantifiable PD-L1 Expression36.4 (17.2 to 59.3)32.0 (14.9 to 53.5)
BASELINE PD-L1 EXPRESSION 1 - 49%38.3 (29.8 to 47.3)23.6 (15.9 to 32.8)
BASELINE PD-L1 EXPRESSION >= 50%50.0 (38.3 to 61.7)31.6 (22.6 to 41.8)
SecondaryPFS by BICR by PD-L1 Tumor Cell Expression

PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
PFS by BICR by PD-L1 Tumor Cell Expression
MonthsTreatment ATreatment B
< 1% PD-L1 Expression5.78 (4.40 to 7.66)4.96 (4.21 to 5.78)
>= 1% PD-L1 Expression6.87 (5.55 to 8.94)4.70 (4.24 to 5.55)
with 1-49% PD-L1 Expression6.74 (4.50 to 8.51)5.29 (4.24 to 5.68)
with >= 50% PD-L1 Expression8.28 (4.44 to 12.48)4.53 (4.14 to 5.65)
Non-Quantifiable PD-L1 Expression6.95 (3.61 to 15.08)6.77 (2.83 to 13.83)
SecondaryOS by PD-L1 Tumor Cell Expression

OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

Time frame:
From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
OS by PD-L1 Tumor Cell Expression
MonthsTreatment ATreatment B
< 1% PD-L1 Expression17.74 (13.67 to 20.27)9.79 (7.69 to 13.54)
>= 1% PD-L1 Expression15.80 (13.77 to 22.18)10.89 (9.49 to 13.17)
with 1-49% PD-L1 Expression15.20 (12.62 to 21.22)10.37 (8.67 to 12.35)
with >= 50% PD-L1 Expression18.91 (13.11 to 29.11)12.93 (9.36 to 17.58)
Non-Quantifiable PD-L1 Expression10.84 (7.16 to 15.57)17.05 (8.64 to NA)
Post-hocOverall Survival (OS)

OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

Time frame:
From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment ATreatment B
Overall Survival (OS)15.80 (13.93 to 19.71)10.96 (9.49 to 12.71)
Statistical analysis
  • Treatment A vs Treatment B · Stratified Cox proportional hazard model · Hazard ratio (hr): 0.74 · 95% CI 0.63 to 0.87
SecondaryPFS by BICR by Tumor Mutational Burden

PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
PFS by BICR by Tumor Mutational Burden
MonthsTreatment ATreatment B
≥ 10 Mutations/MB8.94 (5.55 to 13.01)4.70 (4.14 to 5.62)
< 10 Mutations/MB5.62 (4.17 to 7.20)5.16 (4.21 to 5.62)
Overall6.37 (5.36 to 8.21)4.96 (4.27 to 5.55)
Not Evaluable6.74 (4.24 to 9.69)5.45 (4.17 to 5.82)
SecondaryORR by BICR by Tumor Mutational Burden

ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.

Time frame:
From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Reported as:
Number · Percentage of Participants
ORR by BICR by Tumor Mutational Burden
Percentage of ParticipantsTreatment ATreatment B
≥ 10 Mutations/MB45.5 (35.6 to 55.8)29.3 (19.7 to 40.4)
< 10 Mutations/MB31.6 (23.9 to 40.1)27.0 (19.8 to 35.3)
Overall37.6 (31.4 to 44.1)27.9 (22.0 to 34.3)
Not Evaluable36.4 (27.8 to 45.8)21.2 (14.7 to 29.0)
SecondaryOS by Tumor Mutational Burden

OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.

Time frame:
From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
Reported as:
Median · Months
OS by Tumor Mutational Burden
MonthsTreatment ATreatment B
≥ 10 Mutations/MB15.05 (12.45 to 20.76)10.76 (7.85 to 15.41)
< 10 Mutations/MB16.51 (11.99 to 19.98)12.55 (10.38 to 14.92)
Overall15.57 (13.34 to 19.38)12.06 (10.35 to 14.06)
Not Evaluable17.10 (13.47 to 25.49)9.46 (8.15 to 11.79)

Adverse events

Collected over 30 days after last dose, assessed up to October 2024, approximately 72 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A304/361 (84.2%)259/358 (72.3%)343/358 (95.8%)
Treatment B318/358 (88.8%)197/349 (56.4%)329/349 (94.3%)
Most frequent serious events
Showing 10 of 287
Most frequent serious events
EventTreatment ATreatment B
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)61/35878/349
PneumoniaInfections and infestations28/35823/349
AnaemiaBlood and lymphatic system disorders11/35818/349
Febrile neutropeniaBlood and lymphatic system disorders15/3589/349
DiarrhoeaGastrointestinal disorders14/3583/349
Respiratory failureRespiratory, thoracic and mediastinal disorders13/3582/349
DyspnoeaRespiratory, thoracic and mediastinal disorders7/35811/349
PneumonitisRespiratory, thoracic and mediastinal disorders11/3585/349
Acute kidney injuryRenal and urinary disorders8/3586/349
ThrombocytopeniaBlood and lymphatic system disorders3/3587/349
Most frequent other events
Showing 10 of 56
Most frequent other events
EventTreatment ATreatment B
AnaemiaBlood and lymphatic system disorders122/358161/349
NauseaGastrointestinal disorders120/358146/349
AstheniaGeneral disorders112/35896/349
Decreased appetiteMetabolism and nutrition disorders112/35888/349
DiarrhoeaGastrointestinal disorders111/35868/349
ConstipationGastrointestinal disorders85/35883/349
PruritusSkin and subcutaneous tissue disorders85/35811/349
FatigueGeneral disorders81/35862/349
RashSkin and subcutaneous tissue disorders76/35816/349
VomitingGastrointestinal disorders71/35861/349

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment ATreatment BTotal
Median65.0 ± 8.365.0 ± 10.365.0 ± 9.4
Age, Customized
Age, Customized(Count of Participants)Treatment ATreatment BTotal
˂65 years old17617849.2
≥65 and ˂75 years old14814741.0
≥75 years old37339.7
≥85 years old020.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTotal
Female109106215
Male252252504
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ATreatment BTotal
Hispanic or Latino293160
Not Hispanic or Latino154158312
Unknown or Not Reported178169347
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ATreatment BTotal
American Indian or Alaska Native101
Asian303060
Native Hawaiian or Other Pacific Islander000
Black or African American549
White322316638
More than one race000
Unknown or Not Reported3811
08

Study locations

116 sites
  • Memorial Health Systems
    Colorado Springs, Colorado 80909, United States
  • Local Institution - 0044
    Plainville, Connecticut 06062, United States
  • Local Institution - 0045
    Jacksonville, Florida 32207, United States
  • Local Institution - 0029
    Marietta, Georgia 30060, United States
  • Local Institution - 0091
    Wichita, Kansas 67214, United States
  • Local Institution - 0004
    Lexington, Kentucky 40503, United States
  • Local Institution - 0105
    Detroit, Michigan 48202, United States
  • Local Institution - 0058
    Johnson City, New York 13790, United States
  • Local Institution - 0098
    Mineola, New York 11501, United States
  • Local Institution - 0095
    Columbus, Ohio 43210, United States
  • Local Institution - 0006
    Lancaster, Pennsylvania 17602, United States
  • Local Institution - 0047
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0093
    Pittsburgh, Pennsylvania 15224, United States
  • Local Institution - 0094
    Charleston, South Carolina 29414, United States
  • Southwest Regional Cancer Clinic
    St. George, Utah 84770, United States
  • Local Institution - 0099
    Madison, Wisconsin 53705, United States
  • Local Institution - 0014
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0028
    Río Cuarto, Córdoba Province 5800, Argentina
  • Local Institution - 0026
    Viedma, Río Negro Province 8500, Argentina
  • Local Institution - 0027
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Local Institution - 0030
    Córdoba, 5000, Argentina
  • Local Institution - 0086
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0040
    Bedford Park, South Australia 5042, Australia
  • Local Institution - 0089
    Box Hill, Victoria 3128, Australia
  • Local Institution - 0036
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0078
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0002
    Gilly, 6060, Belgium
  • Local Institution - 0033
    Leuven, 3000, Belgium
  • Local Institution - 0001
    Roeselare, 8800, Belgium
  • Local Institution - 0068
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Local Institution - 0063
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0067
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0069
    Blumenau, Santa Catarina 89010-340, Brazil
  • Local Institution - 0064
    Barretos, São Paulo 14780-070, Brazil
  • Local Institution - 0065
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Local Institution - 0066
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0070
    São Paulo, 01327-001, Brazil
  • Local Institution - 0090
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 0083
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0082
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0080
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0059
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0084
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0079
    Viña del Mar, Valparaiso 2520612, Chile
  • Local Institution - 0139
    Beijing, BEI 100142, China
  • Local Institution - 0146
    Haikou, Hainan 570311, China
  • Local Institution - 0148
    Zhengzhou, Henan 450003, China
  • Local Institution - 0120
    Zhengzhou, Henan 450052, China
  • Local Institution - 0144
    Changsha, Hunan 410000, China
  • Local Institution - 0106
    Changchun, Jilin 130012, China
  • Local Institution - 0108
    Xi'an, Shan3xi 710038, China
  • Local Institution - 0110
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0111
    Zhejiang, Zhejiang 310022, China
  • Local Institution - 0113
    Beijing, 102206, China
  • Local Institution - 0112
    Shanghai, 200030, China
  • Local Institution - 0010
    Bron, Auvergne-Rhône-Alpes 69500, France
  • Local Institution - 0009
    Lyon Cedex08, Auvergne-Rhône-Alpes 69373, France
  • Local Institution - 0013
    Caen, 14033, France
  • Local Institution - 0071
    Lille, 59037, France
  • Local Institution - 0012
    Montpellier, 34295, France
  • Local Institution - 0035
    Nantes, 44093, France
  • Local Institution - 0011
    Paris, 75970, France
  • Local Institution - 0097
    Saint-Brieuc, 22027, France
  • Local Institution - 0073
    Berlin, 14165, Germany
  • Local Institution - 0016
    Gauting, 82131, Germany
  • Local Institution - 0072
    Großhansdorf, 22927, Germany
  • Local Institution - 0019
    Hemer, 58675, Germany
  • Local Institution - 0017
    Immenhausen, 34376, Germany
  • Local Institution - 0074
    Magdeburg, 39120, Germany
  • Local Institution - 0015
    München, 81925, Germany
  • Local Institution - 0018
    Stuttgart, 70376, Germany
  • Local Institution - 0021
    Dublin, 8, Ireland
  • Local Institution - 0020
    Limerick, V94 F858, Ireland
  • Local Institution - 0042
    Lucca, 5510, Italy
  • Local Institution - 0041
    Milan, 20132, Italy
  • Local Institution - 0043
    Naples, 80131, Italy
  • Local Institution - 0101
    Fukushima, Fukushima 9601295, Japan
  • Local Institution - 0118
    Maebashi, Gunma 3718511, Japan
  • Local Institution - 0128
    Ota-shi, Gunma 3738550, Japan
  • Local Institution - 0138
    Hiroshima, Hiroshima 7308518, Japan
  • Local Institution - 0137
    Hiroshima, Hiroshima 7348511, Japan
  • Local Institution - 0127
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 0131
    Akashi-shi, Hyōgo 6738558, Japan
  • Local Institution - 0119
    Himeji-shi, Hyōgo 6708520, Japan
  • Local Institution - 0104
    Kobe, Hyōgo 6500047, Japan
  • Local Institution - 0115
    Kanazawa, Ishikawa-ken 9208641, Japan
  • Local Institution - 0100
    Shiwa-gun, Iwate 0283695, Japan
  • Local Institution - 0129
    Yokohama, Kanagawa 2210855, Japan
  • Local Institution - 0114
    Yokohama, Kanagawa 2360051, Japan
  • Local Institution - 0134
    Yokohama, Kanagawa 2418515, Japan
  • Local Institution - 0116
    Niigata, Niigata 9518566, Japan
  • Local Institution - 0136
    Okayama, Okayama-ken 7008558, Japan
  • Local Institution - 0135
    Habikino-shi, Osaka 5838588, Japan
  • Local Institution - 0103
    Ōsaka-sayama, Osaka 5898511, Japan
  • Local Institution - 0102
    Kitaadachi-gun, Saitama 3620806, Japan
  • Local Institution - 0132
    Ube-shi, Yamaguchi 7550241, Japan
  • Local Institution - 0130
    Osaka, 545-8586, Japan
  • Local Institution - 0077
    La Paz, BAJA Californa SUR 23040, Mexico
  • Local Institution - 0061
    Guadalajara, Jalisco 44280, Mexico
  • Local Institution - 0075
    Veracruz, Veracruz, 91900, Mexico

Showing the first 100 of 116 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4. PubMed 39369790 ↗
  • Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J, Cheng Y, Mizutani H, Zurawski B, Alexandru A, Carbone DP, Lu S, John T, Aoyama T, Grootendorst DJ, Hu N, Eccles LJ, Paz-Ares LG. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024 Nov;211:114296. doi: 10.1016/j.ejca.2024.114296. Epub 2024 Aug 25. PubMed 39270380 ↗
  • Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Perol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. PubMed 33476593 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2019, 23 months.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2017
First posted
Jul 12, 2017
StartActual
Aug 24, 2017
Primary completionActual
Aug 16, 2019
CompletionActual
Oct 18, 2024
Results first posted
Sep 16, 2020
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03215706
Responsible party
Sponsor
First posted
Jul 12, 2017
Start date
Aug 24, 2017
Primary completion
Aug 16, 2019
Completion
Oct 18, 2024
Results posted
Sep 16, 2020
Last update
Dec 17, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion